Allergan

Allergan Launches New BOTOX Cosmetic “Own Your Look” Consumer Campaign

Botox Cosmetic Consumer Campaign

Allergan is launching a new direct-to-consumer campaign for Botox Cosmetic (onabotulinumtoxinA) entitled “Own Your Look.” The campaign is designed to address the most common concerns around BOTOX Cosmetic—fear of looking unnatural—and to encourage people to own their looks and aesthetic choices.

This is the first campaign from the brand created specifically to address millennial women and men who are increasingly curious about aesthetic treatments, while continuing to speak to the BOTOX Cosmetic core consumer (women ages 34 – 45).

Allergan Announces Results of Higher-Dose BOTOX Cosmetic for Glabellar Lines

Higher Dose Botox for Better Longevity

Higher doses of Botox Cosmetic are well tolerated and offer better longevity than the traditional 20-unit dose, according the results of a new clinical study. Allergan conducted a trial to evaluate the duration of effect and safety of Botox Cosmetic at 40, 60 and 80 unit doses versus the 20-unit dose in patients with moderate-to-severe glabellar lines. The primary efficacy endpoint of ≥1 point improvement in Facial Wrinkle Scale (FWS) from baseline was met and was statistically significant for 40, 60 and 80 units versus 20 units in 226 subjects at 24 weeks.

Allergan to Acquire Bonti

Allergan has agreed to acquire Bonti, a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development: EB-001A (aesthetic) and EB-001T (therapeutic).

Allergan Launches Spotlyte Digital Hub

New consumer education hub launches

Allergan has launched Spotlyte, a digital hub of curated content designed to help consumers learn more about medical aesthetic treatments. The site features researched content, product reviews and insider profiles, together with the latest beauty news and trends. In addition to its editorial content, Spotlyte will provide consumers access to a team of trained specialists who can chat directly with anyone considering medical aesthetic treatments and help connect them to local licensed providers.

Allergan Acquires Regenica Line With Plans To Expand Histogen Growth Factor Technology

Growth Factor-Based Skin Care

Allergan has acquired the Regenica growth factor-based skincare line, and will market the line’s proprietary multipotent cell-conditioned media, which was developed by regenerative medicine company Histogen. Allergan plans to incorporate the technology, known as Multipotent Resignaling Complex (MRCx), in future products under the SkinMedica portfolio.

Allergan CEO Questions Medical Aesthetic Treatment for Minors

Allergan CEO pushes for consensus on cosmetic treatment of minors

Allergan Chairman and CEO Brent Saunders authored a blog post from the CEO on the company’s website in which he shared his concern and discomfort with the growing number of minors undergoing cosmetic enhancement. In the post, he encouraged the medical aesthetics industry to start a dialogue on this topic in an effort to find consensus and provide guidelines for the treatment of minors. Following is Saunder’s post in full:

American Skin Association Honors Three at 30-Year Celebration

On Monday, March 27, the American Skin Association (ASA) celebrated its 30 years anniversary by presenting awards to three honorees who have made a significant impact in the areas of skin health and research. The ASA and its affiliates have funded more than $50 million in grants to support the work of more than 300 promising young scientists. In addition, the organization works to educate the public on skin health through its ASA Education Council. Monday night's honorees included:

Allergan To Acquire Zeltiq

Allergan has entered into an agreement to acquire Zeltiq Aesthetics, maker of the CoolSculpting system, for roughly $2.475 billion. The sale is expected to close in the second half of 2017. “The acquisition of Zeltiq is highly complementary and strategic to Allergan. By adding the best-in-class body contouring CoolSculpting System to our best-in-class facial aesthetics, plastic surgery and regenerative medicine offerings we are creating a world-class aesthetics business,” said Brent Saunders, chairman and CEO of Allergan.